Abstract
A simple, efficient and ecofriendly procedure for the synthesis of tetrahydrobenzo[b]pyran derivatives using triphenylphosphine as catalyst under aqueous conditions has been developed. This new method has some advantages like the easy experimental protocol, shorter reaction time, higher yields and is benign for the environment with using water as solvent.
Keywords: Aqueous medium, multicomponent reaction, one-pot synthesis, Tetrahydrobenzo[b]pyrans, triphenylphosphine
Letters in Organic Chemistry
Title:Triphenylphosphine-Catalyzed One-Pot Three Component Synthesis of Tetrahydrobenzo[b]Pyrans in Aqueous Medium
Volume: 10 Issue: 2
Author(s): Wassima Ghalem, Ramzy Hilal Sedrati, Nadjiba Benloucif, Fabienne Berree, Boudjemaa Boumoud and Abdelmadjid Debache
Affiliation:
Keywords: Aqueous medium, multicomponent reaction, one-pot synthesis, Tetrahydrobenzo[b]pyrans, triphenylphosphine
Abstract: A simple, efficient and ecofriendly procedure for the synthesis of tetrahydrobenzo[b]pyran derivatives using triphenylphosphine as catalyst under aqueous conditions has been developed. This new method has some advantages like the easy experimental protocol, shorter reaction time, higher yields and is benign for the environment with using water as solvent.
Export Options
About this article
Cite this article as:
Ghalem Wassima, Hilal Sedrati Ramzy, Benloucif Nadjiba, Berree Fabienne, Boumoud Boudjemaa and Debache Abdelmadjid, Triphenylphosphine-Catalyzed One-Pot Three Component Synthesis of Tetrahydrobenzo[b]Pyrans in Aqueous Medium, Letters in Organic Chemistry 2013; 10 (2) . https://dx.doi.org/10.2174/1570178611310020015
DOI https://dx.doi.org/10.2174/1570178611310020015 |
Print ISSN 1570-1786 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6255 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
subject Index To Volume 2
Current Molecular Medicine CypD: The Key to the Death Door
CNS & Neurological Disorders - Drug Targets TRPV1 Antagonists as a Potential Treatment for Hyperalgesia
Recent Patents on CNS Drug Discovery (Discontinued) Neuroprotective Methodologies of Co-Enzyme Q10 Mediated Brain Hemorrhagic Treatment: Clinical and Pre-Clinical Findings
CNS & Neurological Disorders - Drug Targets Technological Advances in Antigen Delivery and Synthetic Peptide Vaccine Developmental Strategies
Mini-Reviews in Medicinal Chemistry Targeting Mitogen-Activated Protein Kinase Phosphatase-1 (MKP-1): Structure-Based Design of MKP-1 Inhibitors and Upregulators
Current Medicinal Chemistry Therapeutic Approach to Multiple Sclerosis by Novel Oral Drugs
Recent Patents on Inflammation & Allergy Drug Discovery Drugs Used to Treat Parkinsons Disease, Present Status and Future Directions
CNS & Neurological Disorders - Drug Targets Antimalarial Drugs in Pregnancy: A Review
Current Drug Safety Editorial: Smart Drug Delivery Systems (Part 1)
Current Drug Targets Patients Driving the Clinical Trial Designs – Democracy in Clinical Research
Reviews on Recent Clinical Trials A Comparative Summary on Antioxidant-like Actions of Timolol with Other Antioxidants in Diabetic Cardiomyopathy
Current Drug Delivery 5-Benzylidene-3,4-dihalo-furan-2-one derivatives inhibit human leukemia cancer cells through suppression of NF-κB and GSK-3β
Anti-Cancer Agents in Medicinal Chemistry Synthesis and Evaluation of N-substituted (Z)-5-(Benzo[d][1,3]dioxol-5- ylmethylene)-2-Thioxothiazolidin-4-one Derivatives and 5-Substituted- Thioxothiazolidindione Derivatives as Potent Anticonvulsant Agents
CNS & Neurological Disorders - Drug Targets Endocannabinoids and Their Receptors: Physiology, Pathology and Pharmacology
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) TRPV1: A Target for Next Generation Analgesics
Current Neuropharmacology GSK3 at the Edge: Regulation of Developmental Specification and Cell Polarization
Current Drug Targets The Development of Antibody-based Immunotherapy for Methamphetamine Abuse: Immunization, and Virus-Mediated Gene Transfer Approaches
Current Gene Therapy Migraine Attack Treatment : A Tailor-made Suit, Not One Size Fits All
Recent Patents on CNS Drug Discovery (Discontinued) Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke Patients Receiving Thrombectomy: Standard or Low Dose Therapy?
Current Neurovascular Research